Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients.
Chronic hepatitis C (CHC) is a common progressive healthcare challenge that leads to liver cirrhosis, liver failure, and hepatocellular carcinoma. The optimum therapy was a combination of pegylated interferon and ribavirin, which was associated with moderate response and severe side effects. Sofosbuvir revolutionized CHC treatment, especially in combination with other antiviral agents. The aim of this study was to compare and evaluate the safety and efficacy of sofosbuvir/daclatasvir versus sofosbuvir/ledipasvir for treatment of non-cirrhotic naïve patients for 12 weeks in CHC patients. The current study was conducted in Hepatology clinic at Beni-Suef general hospital. One hundred patients (70 females, 30 males) were recruited from Hepatology clinic at Beni-Suef general hospital. Patients were randomly allocated into two groups that received a 12 weeks treatment of either sofosbuvir 400 mg/daclatasvir 60 mg or sofosbuvir 400 mg/ledipasvir 90 mg. The sustained virological response 12 weeks post treatment (SVR12) (HCV RNA < Lower Limit of Quantification (LLOQ)) was determined to evaluate efficacy. The clinical laboratory tests and any reported adverse effects from the first dose administration till 30 days after the last dose were assessed to evaluate safety. Assessment of the safety, efficacy and compliance of sofosbuvir/daclatasvir versus sofosbuvir/ledipasvir for treatment of non-cirrhotic naïve patients for 12 weeks in CHC patients. SVR12 was achieved by 98% and 96% of patients receiving sofosbuvir plus ledipasvir and sofosbuvir plus daclatasvir, respectively. The most common adverse events reported were headache, and fatigue. No patients discontinued treatment due to adverse events. The findings from this study suggest that 12 weeks' treatment of sofosbuvir plus daclatasvir and sofosbuvir plus ledipasvir was both efficacious and well tolerated treatment in Egyptian patients with HCV genotype 4 infection.